Cel-Sci shares jump af­ter FDA lifts hold; New up­start is look­ing for Eu­ro mar­ket­ing pacts with biotech

⇨ Shares at mi­cro­cap biotech Cel-Sci $CVM jumped 36% af­ter the biotech an­nounced that the FDA has lift­ed the clin­i­cal hold on its Phase III study of Mul­ti­kine for head and neck can­cer. Re­searchers have re­cruit­ed 928 front­line pa­tients for this study. The pri­ma­ry end­point is a 10% in­crease in over­all sur­vival.

⇨ Here’s a new op­tion for biotechs to take a look at. A group that in­cludes ex-Bio­gen CEO Jim Mullen has formed a new com­pa­ny — clev­er­ly named Vic­ar­ius — which is look­ing to do deals where it un­der­takes the Eu­ro­pean mar­ket­ing for new drugs. This is one pos­si­ble al­ter­na­tive to go­ing it alone or out­li­cens­ing Eu­ro­pean mar­ket­ing rights for some loess-than-ide­al re­turns.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.